A patient with an invasive fungal infection may enter care with symptoms that overlap other infections while the diagnostic answer arrives too late to shape early therapy. Delayed recognition compounds the problem because fungal disease may not enter the differential early enough for testing to begin at all. The delay changes the buying equation. Assay accuracy matters, yet timing determines whether a result influences treatment or becomes retrospective confirmation. Procurement teams should look closely at where testing sits in the clinical pathway and how quickly a usable answer reaches the clinician. The method also has to fit the point at which therapy decisions are made. A technically strong assay loses practical value when specimen transport or batching pushes the result beyond that window.
Thank you for Subscribing to Healthcare Business Review Weekly Brief
